SAN DIEGO, Nov. 3, 2015 /PRNewswire/ -- aTyr Pharma (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, today announced the Company's participation at the 24th Annual Credit Suisse Healthcare Conference to be held at The Phoenician in Scottsdale, AZ, November 9-11.
John Mendlein, aTyr's CEO and Executive Chairman, will provide an overview of the Company during a presentation at 7:30 a.m. MST on Wednesday, November 11, 2015. The presentation will be webcast live through the "Investors" section of the Company website at www.atyrpharma.com. An audio replay will be available for 30 days following the initial presentation webcast.
About aTyr Pharma aTyr Pharma engages in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company's lead candidate, Resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMIC). Resolaris™ is currently in a Phase 1b/2 clinical trial in adult patients with FSHD, as well a Phase 1b/2 trial in adult patients with LGMD2B or FSHD. Trials are planned in additional RMIC indications, including a study of patients with an early onset form of FSHD as well as an initial trial in rare pulmonary diseases with an immune component (RPIC) in patients with interstitial lung disease (ILD). To protect this pipeline, aTyr built an intellectual property estate comprising 45 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by aTyr. aTyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation for which there are currently limited or no treatment options. For more information, please visit http://www.atyrpharma.com.
SOURCE aTyr Pharma